Urinary Tract Infection (UTI) in Males


Practice Essentials

Urinary tract infections (UTIs) are rare in adult males younger than 50 years but increase in incidence thereafter. Causes of adult male UTIs include prostatitis, epididymitis, orchitis, pyelonephritis, cystitis, urethritis, and urinary catheters. Owing to the normal male urinary tract’s many natural defenses to infection, many experts consider UTIs in males, by definition, to be complicated (ie, more likely to be associated with anatomic abnormalities, requiring surgical intervention to prevent sequelae).

Signs and symptoms

Dysuria is the most frequent chief complaint in men with UTI. The combination of dysuria, urinary frequency, and urinary urgency is about 75% predictive for UTI, whereas the acute onset of hesitancy, urinary dribbling, and slow stream is only about 33% predictive for UTI.

Relevant clinical history includes the following:

See Clinical Presentation for more detail.


Perform a thorough physical examination in males presenting with genitourinary complaints. Focus particularly on the patient’s vital signs, kidneys, bladder, prostate, and external genitalia.

Examination findings may include the following:

Laboratory testing

The workup of male UTI depends on the suspected diagnosis.

Routine laboratory studies include urine studies, such as urinalysis, Gram staining, and urine culture. The threshold for establishing true UTI includes finding 2-5 or more white blood cells (WBCs) or 15 bacteria per high-power field (HPF) in a centrifuged urine sediment. In patients with systemic signs such as significant fever, chills, and/or back pain, blood cultures should be drawn. Blood cultures should also be obtained in the setting of S aureus UTI, since this may represent the sustained bacteremia of endocarditis.[1, 2]

Note that a positive nitrite test is poorly sensitive but highly specific for UTI; false-positives are uncommon. Proteinuria is commonly observed in UTIs, but it is usually low grade. More than 2g of protein per 24 hours suggests glomerular disease.

Imaging studies

Consider imaging and urologic intervention in patients with the following:

If concomitant obstructive uropathy is suspected, this is an emergent condition that requires prompt intervention, including the following imaging studies of the urinary system:

See Workup for more detail.


In general, all male UTIs are considered complicated. Consider the potential for renal involvement when planning treatment strategies.

Inpatient management is recommended for patients with the following features:

Initial inpatient treatment includes the following:

Other medications used in the management of male UTIs—or etiologic conditions such as prostatitis; epididymitis; pyelonephritis; or cystitis/urethritis—include the following:

Broaden the antimicrobial coverage and add an antipseudomonal agent in patients with risk factors associated with an unfavorable prognosis (eg, old age, debility, renal calculi, recent hospitalization or instrumentation, diabetes, sickle cell anemia, underlying carcinoma, or intercurrent cancer chemotherapy).


Surgical intervention may be required in the patients with the following conditions:

See Treatment and Medication for more detail.


The incidence of true urinary tract infection (UTI) in adult males younger than 50 years is low (approximately 5-8 per year per 10,000), with adult women being 30 times more likely than men to develop a UTI. The incidence of UTI in men approaches that of women only in men older than 60 years. (See Epidemiology.)

The causes of male UTI addressed in this article include prostatitis, epididymitis, orchitis, and—as they apply to adult males—pyelonephritis, cystitis, and urethritis. Nosocomial urinary tract infections (UTIs) and their main risk factor, indwelling urethral catheters, are also discussed, with attention directed to unique aspects of the male urinary system. (See Pathophysiology, Etiology, Workup, and Treatment.)

For special hosts (eg, patients with spinal injury, diabetes, or transplants) and special conditions (eg, candiduria, perirenal abscess), see more detailed discussions in Cystitis in Females and Pediatric Urinary Tract Infection.

For issues relating to multidrug-resistant organisms (eg, Acinetobacter) or particular organism infections (eg, gonorrhea, schistosomiasis), consult those specific articles.


Complications of acute bacterial prostatitis include bacteremia, septic shock, prostatic abscess, epididymitis, seminal vesiculitis, and pyelonephritis. Suspect a prostate abscess if fever does not resolve within 48 hours; if confirmed, add anaerobic coverage and arrange for drainage. (See Prognosis.)

Gonococcal and nongonococcal urethritis may progress to prostatitis, epididymitis, or orchitis, especially in younger patients. Urethral strictures (secondary to inflammation within the urinary tract) may form in up to 5% of patients; this must be kept in mind when evaluating patients with residual obstructive symptoms after treatment.

Other complications from UTI include fistula formation, recurrent infection, bacteremia, hydronephrosis and pyonephrosis, and gram-negative sepsis. Pyonephrosis refers to infected hydronephrosis associated with suppurative destruction of the kidney parenchyma, which results in nearly total loss of renal function.

Complication risk factors appear to be prolonged use of aminoglycosides (>2wk), high serum trough levels (>2), advanced age, baseline renal insufficiency, concomitant conditions (eg, diabetes mellitus), and concomitant nephrotoxic drugs (eg, amphotericin B). (See Presentation and Workup.)

Patient education

For patient education information, see the Cancer Center and the Men's Health Center, as well as Urinary Tract Infections (UTIs), Prostate Infections, Epididymitis, Inflammation of the Testicle (Orchitis), Urethritis in Men, and Bladder Cancer.


The normal male urinary tract has many natural defenses to infection. Transitional epithelium conducts urine from the kidneys to an elastic bladder, which can store large volumes at low pressures. The male urethra is separated from the rectum by several centimeters of keratinized squamous epithelium; the long urethra provides an additional barrier between the bladder and the perineum.

Because of these many defenses, many experts consider UTIs in males, by definition, to be complicated. Complicated infections are those that are more likely to be associated with anatomic abnormalities, requiring surgical intervention to prevent sequelae. The diagnosis and treatment of UTIs in males should proceed with this concept in mind.

UTIs can be divided anatomically into upper- and lower-tract infections. In the male, lower-tract disease includes prostatitis, epididymitis, cystitis, and urethritis. Upper-tract disease (pyelonephritis) is similar in males and females. The phrase "significant bacteriuria" is sometimes used to emphasize that the number exceeds that which might be caused by contamination during the collection of the specimen. Bacteriuria can be symptomatic or asymptomatic.


As with females, the usual route of inoculation in males is with gram-negative aerobic bacilli from the gut, with Escherichia coli being the most common offending organism. Recent hospitalization, urinary catheter, and fluoroquinolone use in the past 6 months are independent risk factors for fluoroquinolone resistance in community-onset febrile E coli UTI. Fluoroquinolone resistance may be a marker of broader resistance, including extended-spectrum beta-lactamase (ESBL) positivity.[4]

In the normal host, UTI may occur due to infection of other portions of the genitourinary tract, typically the prostate. Older males with prostatic hypertrophy have incomplete bladder emptying, predisposing them to UTI on the basis of urinary stasis. However, in males aged 3 months to 50 years, the incidence of UTI is low; therefore, the possibility of an anatomic abnormality must be entertained in this age group.

Entry of microorganisms into the prostate gland almost always occurs via the urethra; with intraprostatic reflux of urine, bacteria migrate from the urethra or bladder through the prostatic ducts. Other possibilities include entry via the hematogenous route, via the lymphatics from the rectum, and during prostate surgery. However, many patients have no known precipitating event.

Prostatic fluid contains various antibacterial substances, including zinc and antibodies, which are lacking in some patients with chronic bacterial prostatitis. Interestingly, acute prostatitis usually does not result in chronic prostatitis, and chronic bacterial prostatitis is usually not antedated by acute prostatitis. Of men referred for prostatitis, less than 10% have either acute or chronic bacterial prostatitis.

Acute and chronic prostatitis

In the 1800s, prostatitis was thought to be secondary to excessive alcohol consumption or physical or sexual activity. It was often associated with gonorrhea and could be fatal or lead to abscess formation. By the 1920s, most cases were attributed to microorganisms, and antibiotics combined with prostate massage were standard therapy after World War II. Although the role of bacteria was questioned in the 1950s, it was reemphasized in 1968 when Meares and Stamey described their "4-glass test."[5]

Acute prostatitis is caused by an acute infection of the entire prostate gland, resulting in fever and localized pain. Microscopically, neutrophilic infiltrates, diffuse edema, and microabscesses may be seen, which may coalesce into larger collections.

Chronic prostatitis may be caused by inflammatory or noninflammatory diseases. This condition may arise via dysfunctional voiding, intraprostatic reflux, chronic exposure to microorganisms, autoimmune mechanisms, irritative urinary metabolites, and as a variant of neuropathic pain. Chronic bacterial prostatitis often produces few or no symptoms related to the prostate, but it is probably the most common cause of relapsing UTI in men.

Chronic prostatitis has been subdivided by the National Institutes of Health (NIH) into the following categories:

Chronic bacterial prostatitis is the most common cause of relapsing UTI in men, with E coli as the main causative organism (80%), but other gram-negative bacteria and enterococci may also be observed. Rare cases may be caused by yeasts (eg, Candida, Blastomyces, Histoplasma, Cryptococcus) and mycobacteria. Whether Staphylococcus epidermidis, S aureus, and diphtheroids are pathogenically significant is doubtful, and the evidence supporting a causative role for Chlamydia and Ureaplasma is not convincing.[6]


Epididymitis is a clinical syndrome caused by infection or inflammation of the epididymis. This condition is the most common cause of acute scrotum in adult male populations. Long-term complications include abscesses, infarction, recurrence, chronic pain, and infertility

The pathophysiology of epididymitis is divided; Chlamydia trachomatis and Neisseria gonorrhoeae are the most common pathogens in patients younger than 35 years, whereas Enterobacteriaceae and gram-positive cocci are frequent pathogens in older patients. In either case, infection results from retrograde ascent of infected urine from the prostatic urethra into the vas deferens and, finally, into the epididymis.


Because of the widespread use of mumps vaccination, orchitis is no longer a common infection in the United States. Orchitis is one of the few genitourinary infections to result from a viral pathogen.

Mumps orchitis occurs in 18% of postpubertal boys infected with the mumps virus. Other viruses that can cause the disease include coxsackie B, mononucleosis, and varicella. Unlike the majority of genitourinary infections, viral particles are spread to the testicle by the hematogenous route. Granulomatous orchitis is rare and results from hematogenous dissemination of tuberculosis, fungi, and actinomycosis.


Pyelonephritis is an infection of the renal parenchyma. Infection usually occurs in a retrograde, ascending fashion from the bladder, but it may occur hematogenously. The ureteral orifice becomes edematous and loses its one-way valve function during infection. Retrograde flow of bacteria into the upper urinary tracts and into the renal parenchyma results in clinical symptoms.

Bacteremia, particularly with virulent organisms such as S aureus, can result in pyelonephritis with focal renal abscesses. Bacterial adherence allows for mucosal colonization and subsequent infection by an ascending route. Whereas type 1 pili are produced by most uropathogenic strains of E coli, P-pili, which bind to the uroepithelial glycosaminoglycan layer, are found in most strains of E coli that cause pyelonephritis. Genotypic factors may affect uroepithelial susceptibility to these adherence molecules. Endotoxin from gram-negative organisms can retard ureteral peristalsis.

E coli is responsible for approximately 25% of cases in males, with Proteus and Providencia causing many remaining infections; Klebsiella, Pseudomonas, Serratia, and enterococci are less frequent.

Bacterial cystitis

Bacterial cystitis without concomitant infection in other portions of the genitourinary tract is believed to be a rare event in males. The abrupt onset of irritative voiding symptoms (eg, frequency, urgency, nocturia, dysuria) and suprapubic pain are clinically diagnostic.

Most cases of bacterial cystitis occur by an ascending mechanism. Bacterial cystitis in the male is uncommon in the absence of anatomic abnormality, defect in bladder emptying mechanism, or urethral catheterization (eg, poor bladder emptying from prostatic obstruction or dysfunctional voiding). Elevated postvoid residuals allow bacteria to multiply to critical levels. High voiding pressures and poor bladder compliance diminish the natural uroepithelial resistance to infection.


Urethritis has been described for thousands of years. The term gonorrhea (gonus meaning seed, rhoia meaning flow) was coined by Galen. The urethral nonsquamous epithelium can be penetrated by N gonorrhoeae, resulting in periurethral microabscesses. Necrotic debris is sloughed into the urethra lumen, producing a milky penile discharge.

Gonococcal urethritis remains the most commonly reported communicable bacterial disease in the United States.

Urinary catheter–associated UTIs

Up to 25% of hospitalized patients have urinary catheters inserted; of these individuals, 10-27% develop UTIs. In fact, UTI accounts for approximately 40% of all nosocomial infections; 15% of these infections occur in clusters and often involve highly resistant organisms.

The single most important risk factor for nosocomial bacteriuria and UTI is the presence of an indwelling urethral catheter; 80% of nosocomial UTIs are associated with the use of urethral catheters. Once the urethral catheter is in place, the daily incidence of bacteriuria is 3-10%. Because most patients who become bacteriuric do so by 30 days, that is a convenient dividing line between short- and long-term catheterization.


Risk factors for UTI and bacterial causes of prostatitis, epididymitis, orchitis, pyelonephritis, cystitis, and urethritis are discussed in this section.

Risk factors

Obstruction from any cause is a major risk factor for the development of UTI, as are instrumentation of the urinary tract, catheterization, and urologic surgery.

In males older than 50 years, prostatic hypertrophy with partial obstruction is the main contributor to the increase in UTI. Risk factors observed more commonly in elderly or institutionalized males include cognitive impairment, fecal or urinary incontinence, and the use of catheters.

Catheter-associated bacteriuria risk factors include female sex, significant comorbid conditions (especially diabetes mellitus), age older than 50 years, lack of systemic antibiotic(s), and a serum creatinine level greater than 2mg/dL.

Risk factors for bacteremia secondary to catheter-associated UTI (CAUTI) are male sex, UTI caused by Serratia marcescens, older age, underlying urologic disease, and an indwelling catheter.

In young men, risk factors for acute cystitis include homosexual behavior with anal intercourse, intercourse with a female infected or colonized with a uropathogen, lack of circumcision, and human immunodeficiency virus (HIV) infection with CD4 counts of 200/μL or less.


Gram-negative uropathogens (eg, Enterobacteriaceae, such as E coli, Klebsiella, and Pseudomonas) are acknowledged pathogens of the prostate. Probable pathogens include Enterococcus and S aureus, and possible pathogens include coagulase-negative Staphylococcus, Chlamydia, Ureaplasma, anaerobes, Candida, and Trichomonas. Acknowledged nonpathogens of the prostate include diphtheroids, lactobacilli, and Corynebacterium. Bacterial pathogens cannot be demonstrated in cases of nonbacterial prostatitis.

Viruses and cell wall–deficient bacteria have a controversial association with prostatitis. Rare cases have been reported from Clostridia and Burkholderia (formerly Pseudomonas) pseudomallei (the causative agent of melioidosis).

Unusual pathogens reported in patients with acquired immunodeficiency syndrome (AIDS) include cytomegalovirus (CMV) and some fungi (Aspergillus, Histoplasma, and Cryptococcus). The prostate is a known reservoir for Cryptococcus neoformans.


Chlamydia trachomatis and N gonorrhoeae are the most common pathogens in patients younger than 35 years with UTI, whereas Enterobacteriaceae and gram-positive cocci are frequent pathogens in older patients.


Orchitis is one of the few genitourinary infections resulting from viral pathogens, such as the mumps, coxsackie B, Epstein-Barr (EBV), and varicella (VZV) viruses. Granulomatous orchitis is rare and results from hematogenous dissemination of tuberculosis, fungi, and actinomycosis. Brucella also been associated with orchitis; clinically, these patients resemble patients with tuberculosis. Colorado tick fever has also been associated with epididymo-orchitis.

Secondary orchitis is a more common condition; it is a late complication of untreated epididymitis.

Pyelonephritis and cystitis

Bacteria responsible for pyelonephritis and cystitis in males include E coli, Klebsiella, Enterobacter, Proteus, Pseudomonas, Serratia, Enterococcus, and Staphylococcus species.


N gonorrhoeae is the most common cause of urethritis in males; nongonococcal causes of urethritis include C trachomatis (in up to 50% of cases), Ureaplasma urealyticum, Trichomonas vaginalis, and herpes simplex virus (HSV). The role of Mycoplasma in urethritis is controversial.

Catheter-associated bacteriuria

Short-term catheters are placed for a mean duration of 2-4 days. The usual indications are for acute illnesses, output measurement, perioperative routine, and acute retention. Approximately 15% of patients develop bacteriuria, usually with a single organism (E coli). Catheter-associated bacteriuria usually resolves after the catheter is removed; however, one third of patients may have symptoms, and bacteremia is the most serious complication. Approximately 10-30% of patients develop a fever, and the risk of postoperative wound infection associated with bacteriuria is increased.

Long-term catheters are placed for chronic medical or neurologic problems, including chronic urinary retention and incontinence. Essentially all patients develop bacteriuria, which is polymicrobial in up to 95% of cases. New pathogens often emerge, whereas many persist because of adherence properties (fimbrial adhesion in Providencia and E coli) or their effect on the local environment (Proteus and Morganella).

Catheter obstruction in long-term catheterization may occur, via an interaction between bacteria, the glycocalyx, protein, and crystals; Proteus mirabilis is a potent producer of urease, which alkalinizes the urine, precipitating struvite and apatite.


Although this article exclusively addresses UTI in males, the clinician should appreciate that the incidence of UTI is much higher in females during adolescence and childbearing years (adult women are 30 times more likely than men to develop a UTI). The incidence of UTI in men approaches that of women only in males older than 60 years; in men aged 65 years or older, 10% have been found to have bacteriuria, as compared with 20% of women in this age group.

Internationally, there is a similar incidence in developed countries; however, in developing countries where men have shorter life spans, the incidence of UTI due to prostatic hypertrophy is lower.

Young men rarely develop UTIs, and the prevalence of bacteruria is 0.1% or less. There is an early peak incidence during the first 3 months of life; in neonates, UTIs occur more frequently in boys than in girls (with a male-to-female ratio of 1.5:1), and they are often part of the syndrome of gram-negative sepsis. The cumulative incidence of symptomatic UTI (including pyelonephritis) in boys during the first 10 years of life has been reported at 1.1-1.6%.

The incidence of true UTI in adult males younger than 50 years is low (approximately 5-8 per year per 10,000). In this population, the symptoms of dysuria or urinary frequency are usually due to sexually transmitted disease (STD)–related infections of the urethra (eg, gonococcal and nongonococcal urethritis) and prostate.[7]

In men older than 50 years, the incidence of UTI rises dramatically (range, 20-50% prevalence), because of enlargement of the prostate, prostatism, debilitation, and subsequent instrumentation of the urinary tract. The spectrum of causative agents is also somewhat broader in these older men.

Prostatitis, epididymitis, urethritis, and orchitis

In contrast to UTI, prostatitis affects men of all ages and, from 1990-1994, accounted for almost 2 million office visits per year in the United States. Prostatitis syndromes account for 25% of male office visits for genitourinary complaints, 8% of visits to urologists, and 1% of visits to primary care physicians. Of these men, 5% have bacterial prostatitis, 64% have nonbacterial prostatitis, and 31% have prostatodynia. Digital examination of the prostate in the setting of probable or possible UTI should be avoided to prevent the risk of inciting bacteremia.

Epididymitis has a bimodal distribution, corresponding to different age groups and pathogens. Most cases in men younger than 35 years are due to sexually transmitted pathogens. Older patients are more likely to have obstructive prostatism or a history of instrumentation or catheterization.

Gonococcal urethritis is more common in ethnic minorities, lower socioeconomic groups, and persons living in urban centers. The risk to a male having intercourse with an infected female is 17%. Some of these associations may be limited by confounding. The peak age for urethritis is 20-24 years.

Mumps orchitis occurs in 18% of postpubertal boys infected with the mumps virus.


In men, the most frequent chief complaint related to urinary tract infection (UTI) is dysuria. In fact, complaints of dysuria, urinary frequency, and urgency are approximately 75% predictive for UTI, whereas the acute onset of hesitancy, urinary dribbling, and slow stream are only approximately 33% predictive for it. Other aspects to inquire about include the following:

In a younger man, the presence of UTI is often associated with anatomic abnormality. In the absence of this history, a detailed sexual history may implicate activities such as sex with a new partner, sex with multiple partners, or other risk-taking behavior associated with sexually transmitted disease (STD)-related urethritis, prostatitis, or epididymitis that may lead to UTI.

Certain patients are at increased risk of urosepsis and complications, such as the very sick and the immunosuppressed, as well as those with a history of genitourinary surgery, a neurogenic bladder, papillary necrosis (sickle cell disease, diabetes, or analgesic abuse), and a history of ureteral stricture or tumor with obstruction.

Physical Examination

Males who present with genitourinary complaints warrant a thorough general physical examination, with particular attention to the vital signs, kidneys, bladder, prostate, and external genitalia.

Auscultation over the upper abdominal quadrants and the costovertebral angles may reveal the bruits of renal artery stenosis, an aneurysm, or an arteriovenous malformation. The costovertebral angles should also be percussed for tenderness. Palpation of the suprapubic area should be performed; a bladder that contains 500mL or more of fluid is often palpable as a suprapubic mass.

The external genitalia should be examined carefully. The penis should be examined for the presence of ulcers or lesions, and special attention should be paid to the urethral meatus for the presence of erythema or discharge. The testes and epididymis must be examined and palpated for tenderness and swelling.

A rectal examination with a 360° sweep of the interior of the rectum followed by careful palpation of the prostate can be performed. However, in patients with suspected acute bacterial prostatitis, palpation can be painful and may lead to bacteremia. Some authorities note that it is of little benefit in diagnosing acute prostatitis and state that prostatic massage should not be conducted in the setting of UTI or urethritis.

Physical findings of UTI may include the following:

Prostatitis Syndromes

These syndromes tend to occur in young and middle-aged men. Symptoms may include pain (in the perineum, lower abdomen, testicles, or penis or with ejaculation), bladder irritation, and, sometimes, blood in the semen.

Acute prostatitis

Acute prostatitis typically presents with spiking fever, chills, malaise, myalgia, dysuria, pelvic or perineal pain, and cloudy urine. Obstructive symptoms can result from swelling of the acutely inflamed prostate, and these range from dribbling and hesitancy to anuria. A less common presentation is with a vague, flulike illness.

Careful examination of the prostate is not contraindicated in acute bacterial prostatitis, but prostatic massage is contraindicated. Upon examination, the prostate is warm, swollen, soft ("boggy"), and extremely tender. The patient may have a fever and appear acutely uncomfortable; hypotension may be noted.

A rectal examination with a 360° sweep of the interior of the rectum followed by careful palpation of the prostate can be performed. However, in patients with suspected acute bacterial prostatitis, palpation can be painful and may lead to bacteremia. Some authorities note that it is of little benefit in diagnosing acute prostatitis and state that prostatic massage should not be conducted in the setting of UTI or urethritis.

Chronic prostatitis

Patients with chronic prostatitis, by definition, have had symptoms for at least 3 months. Although this condition is not life threatening, the patient's quality of life has been compared with someone with unstable angina or active Crohn disease. Interestingly, many men with chronic bacterial prostatitis are asymptomatic.

Chronic bacterial prostatitis and nonbacterial prostatitis have similar presentations, including dysuria, frequency, urgency, perineal discomfort, and a low-grade temperature. The only way to differentiate between these 2 entities is through culture of prostatic secretions.

Prostatodynia, a noninflammatory disorder, also has a symptom complex similar to that of chronic prostatitis, except that the patient does not give a history of recurrent UTIs.

In chronic bacterial prostatitis, the physical findings are variable. A low-grade fever may be present, and the rectal examination may be unremarkable or may reveal severe anal sphincter spasm. The prostate may be mildly or extremely tender.

Examination of urine voided after prostate massage is more helpful diagnostically than quantitating the amount of pain experienced during the digital examination. The Meares-Stamey 4-glass test with prostatic massage is a classic diagnostic test for chronic prostatitis. Prostatic massage should not be conducted in the setting of UTI or urethritis.

Epididymitis and Cystitis

In early epididymitis, the epididymis is tender and indurated, but the testis itself is nontender and soft. In hours to days, inflammation progresses to the adjacent testicle and patients may complain of scrotal pain and swelling, as well as urinary frequency, urgency, or dysuria. Identifying the lateral sulcus between the testicle and epididymis then becomes increasingly difficult, and discerning testis from epididymis may be impossible.

Dysuria, frequency, urgency, and suprapubic pain usually are present in patients with cystitis. Fever and flank pain may be present, but not usually. Note that symptoms cannot reproducibly differentiate cystitis (lower UTI) from pyelonephritis (upper UTI).


The most common presentation of orchitis is in a patient in the later stages of epididymitis. In this situation, inflammation has spread to the adjacent testicle and results in a tender, warm, and swollen hemi-scrotal mass. Patients have the characteristic history and urinary findings of epididymitis.

Of patients with orchitis resulting from tuberculosis, 70% have other genitourinary or pulmonary symptoms of this disease.

Viral orchitis is notable for the symptoms of the viral syndrome. Orchitis occurs in approximately 18% of postpubertal boys infected with the mumps virus; symptoms usually begin within 1 week of parotitis. Up to 30% of cases are bilateral, and sterility develops in up to 10% of cases.


Patients with pyelonephritis appear ill; have fever, chills, and flank pain; and may have hypotension. Although fever is very suggestive of pyelonephritis, it has also been demonstrated in some males with simple cystitis. Note that 30-50% of pyelonephritis cases may be silent, without clinical symptoms.

In the older male, prostate enlargement along with delayed presentation are the primary causes of pyelonephritis. Other historical risk factors include nephrolithiasis, neurogenic bladder, prostatitis, or symptom duration greater than 5 days.

Classic findings with pyelonephritis include fever, chills, and flank pain/costovertebral angle tenderness that follow the symptoms of UTI; these findings are combined with pyuria and bacteriuria. Occasionally, the urinalysis and urine culture findings are negative, such as when an obstruction of the upper urinary tract is present due to stone disease.

The differential diagnoses include appendicitis, diverticulitis, pancreatitis, and lower-lobe pneumonia.


The incubation period of gonococcal urethritis is 2-6 days. Occasionally, 2 weeks may elapse before symptoms such as dysuria; thick, milky discharge; and pruritus occur.

The incubation period of nongonococcal urethritis (NGU) is 2-6 weeks. The symptoms are less severe and the discharge may be clearer than with gonococcal urethritis. Patients are likely to have a higher level of education (ie, 90% of urethritis cases in college health services is NGU) and fewer sexual contacts.

Because patients with urethritis have a thick, milky discharge, the underpants may be impressively stained. Typically, patients with gonorrhea have a thicker, more copious discharge, but significant overlap with chlamydial urethritis is not uncommon.

Gram stain is the key to an immediate diagnosis, although patients frequently have co-infections.

Catheterized and Hospitalized Patients

Clinical and microbiologic criteria for the diagnosis of UTI are not well established in catheterized hospitalized patients. Symptoms in these individuals may be atypical or may be attributed to other disease processes, and no reliable colony count cutoff defines significant bacteriuria.

Low-level (100-1000 colony-forming units [CFU] per mL) colonization can progress to high-level (>100,000 CFU/mL) bacteriuria within 3 days in 96% of catheterized patients who are cultured on subsequent days (and not treated with antimicrobials). Thus, most experts agree that growth of more than 100 CFU/mL of a predominant pathogen represents catheter-associated UTI (CAUTI).

Approach Considerations

The workup of urinary tract infections (UTIs) is dependent on the suspected diagnosis; however, routine studies include urine studies, such as urinalysis, Gram staining, and urine culture. The threshold for establishing true UTI includes finding 2-5 or more white blood cells (WBCs) or 15 bacteria per high-power field (HPF) in a centrifuged urine sediment.

As with females, a positive nitrite test is poorly sensitive but highly specific for UTI, and false-positives are uncommon.

Proteinuria is commonly observed in UTIs, but the proteinuria is usually low-grade. More than 2g of protein per 24 hours suggests glomerular disease.

The older patient who appears toxic, has diabetes, or is immunocompromised may be at risk for emphysematous pyelonephritis; radiographic studies (eg, kidney, ureters, bladder [KUB]) may be necessary to exclude this possibility.

Urine Studies

Urine specimens may be obtained by suprapubic aspiration, catheterization, or midstream clean catch. Most males can perform a midstream clean catch reasonably well, with a reliability approaching that of suprapubic aspiration. Uncircumcised men must retract the prepuce and cleanse the glans before obtaining a specimen. If the patient is unable to cooperate, a catheterized specimen or suprapubic aspiration is necessary.

Bacteriuria without pyuria suggests contamination or colonization. Pyuria without bacteriuria suggests nongonococcal urethritis (NGU), genitourinary tuberculosis, stone disease, or malignancy.

If a Gram stain of an uncentrifuged clean-catch midstream urine sample reveals the presence of 1 bacterium per oil-immersion field, this represents 10,000 bacteria/mL of urine. A specimen (5mL) that has been centrifuged for 5 minutes at 2000 revolutions per minute (rpm) and examined under high power after Gram staining allows for the identification of bacteria in lower numbers. In general, Gram staining has a sensitivity of 90% and a specificity of 88%.

Urine culture remains the criterion standard for the diagnosis of UTI. Collected urine should be immediately sent for culture; if not, it should be refrigerated at 4°C. Two culture techniques (dip slide, agar) are used widely and are accurate.

The exact number of bacteria in a urine culture that is needed to define UTI in a man is a bit controversial; generally, positive results are seen if there are more than 1000 colony-forming units (CFU)/mL of urine, much lower than the threshold for women.[8] However, most authors would accept a value of more than 10,000 CFU/mL. Some advocate the treatment of any pathogens growing in a patient with symptoms of UTI.

Imaging Studies

Imaging and urologic intervention should be considered in the following patients:

Imaging in the emergency department is typically not necessary unless concomitant obstructive uropathy is suspected, as this is an emergent condition that requires prompt intervention. Modalities for this include ultrasonography, contrasted computed tomography (CT) scanning, or helical CT scanning of the urinary system (currently preferred by most experts).

Plain film imaging

Plain films may localize stone densities, but identification within the urinary tract cannot be confirmed. Uric acid and some struvite stones are radiolucent. Plain films provide no information about the renal parenchyma or function.


Measurement of the postvoid residual by bladder scan or ultrasonography should be performed on every patient admitted to the hospital for UTI. Its use may minimize the need for Foley catheter insertion.

Renal ultrasonography is a noninvasive study that requires no contrast and provides useful information about the renal parenchyma. This imaging modality can be performed at the bedside in a hemodynamically unstable patient, and it can help to detect hydronephrosis, pyonephrosis, and perirenal abscess. However, the quality of the study depends on the skill of the examiner; the study may be of little benefit in patients who are obese. Ureteral dilatation secondary to UTIs may mimic obstruction.

Transrectal ultrasonography is the study of choice to demonstrate a prostate abscess;[9] a CT or magnetic resonance imaging (MRI) scan may also be useful. Virtually all men older than 60 years have some prostatic calculi (see the CT scan below); however, no correlation exists between chronic prostatitis and the presence or absence of prostatic calculi.

View Image

Prostatic calcifications in a male with a urinary tract infection.

Scrotal ultrasonography with Doppler interrogation and radionuclide scans can be helpful in equivocal cases to differentiate the causes of acute scrotum, including epididymitis, torsion of the spermatic chord, and torsion of a testicular appendage. Torsion of the spermatic cord must be assumed until proven otherwise, because necrosis can develop in less than 3 hours. Consultation with a urologist is mandatory in all but the most clear-cut cases of torsion, because the standard is to try to intervene in less than 3 hours.

CT scanning

Noncontrast helical CT scanning is the preferred diagnostic test for obstructive nephrolithiasis. CT scanning with contrast is the imaging study of choice, offering excellent information about the renal parenchyma and the collecting system. It is also a functional study when the excretory phase is included, which demonstrates the site and degree of obstruction very well.

Histologic Findings

In acute bacterial prostatitis, inflammation is observed in part or all of the gland. This is characterized by marked infiltration with neutrophils and diffuse edema. Microabscesses may be present, and these may coalesce into larger collections.

The histology of chronic bacterial prostatitis is that of focal, nonacute inflammation; however, this finding is not diagnostic, because it may be observed in men without bacterial infection. Because chronic bacterial prostatitis may be a focal disease, needle biopsies may be unreliable. Occasionally, biopsies reveal a granulomatous prostatitis of unknown cause.

Pyuria Workup

The most accurate method to measure pyuria is counting leukocytes in unspun fresh urine using a hemocytometer chamber; more than 10 WBCs/mL is considered abnormal. Examination for pyuria is a sensitive (80-95%), but nonspecific (50-76%), method of diagnosing UTI. WBC counts determined from a wet mount of centrifuged urine are not reliable measures of pyuria. An uncontaminated specimen is suggested by a lack of squamous epithelial cells.

White cell casts in urine specimens may be observed in conditions other than infection, and they may not be observed in all cases of pyelonephritis. If the patient has evidence of acute infection and white cell casts are present, the infection likely represents pyelonephritis. A spun sample (5mL at 2000rpm for 5min) is best used for evaluation of cellular casts.

The presence of leukocyte esterase on a dipstick test is a rapid screening for pyuria; it is 57-96% sensitive and 94-98% specific for identifying pyuria.

The nitrite test is a rapid screening test for bacteriuria; false-negative test results are seen in low-grade bacteriuria, but false-positive results are rare. A positive nitrite test has 27% sensitivity and 94% specificity for UTI when the cutoff is 100,000 CFU/mL.

Prostatitis Workup

In acute bacterial prostatitis, most patients have pyuria and bacteruria, allowing the infecting organism to be isolated by midstream urine collection. Blood cultures, a complete blood count (CBC), and a basic metabolic panel should be obtained.

In chronic bacterial prostatitis, bacteria and leukocytes may or may not be observed in prostate-specific secretions (ie, expressed prostatic secretions [EPS] or a third midstream bladder specimen [VB3] postprostatic massage). More than 15 leukocytes/HPF is abnormal.

4-Glass test

Although the 4-glass test is the standard for the diagnosis of chronic prostatitis, it is used infrequently.

The 4-glass test was described by Meares and Stamey in 1968 to accurately localize bacteria (ie, urethra vs prostate).[5] One should obtain simultaneous cultures of: (1) urethral urine,(ie, first voided bladder specimen [VB1]); (2) midstream urine (ie, second midstream bladder specimen [VB2]); (3) EPS; and (4) VB3.

The tests should be performed when the patient does not have significant bacteruria, and the specimens must be quantitatively cultured immediately after collection.

If bacteruria is present, ampicillin, cephalexin, or nitrofurantoin should be given for 2-3 days to sterilize the urine; these agents are not effective against chronic bacterial prostatitis. If the number of bacteria in EPS ejaculate or VB3 exceeds that in VB1 or VB2 by at least 10-fold, the infection is prostatic in origin.

Premassage/postmassage test

A simpler procedure for the diagnosis of chronic prostatitis was suggested by Nickel.[10] In the premassage and postmassage test, urine is obtained before and after prostate massage. These specimens are sent for culture and sediment microscopy. If bacteria and leukocytosis in the postmassage specimen exceed those in the premassage specimen, category II prostatitis is suggested. Leukocytosis alone indicates category IIIA, whereas no bacteria or leukocytosis indicates category IIIB.

Postvoid residual urine volume measurement

Measurement of the postvoid residual urine volume may be helpful in the older patient for whom prostatism is suspected. Although this measurement is traditionally performed via catheterization, some institutions are now using ultrasonography for this measurement.[11] If the postvoid residual urine volume is elevated, then a urinary catheter must be placed and urologic consultation obtained.

Urodynamic studies

Chronic prostatitis may result in an element of bladder neck obstruction, which may be demonstrated by urodynamic studies and may be corrected with transurethral surgery.[3]

Epididymitis and Orchitis Workup

In epididymitis, a microscopic examination of the urethral secretions is helpful only in cases with very mild symptoms, when torsion is not a consideration. Leukocytes and bacteria on a Gram stain would suggest epididymitis (unless the patient previously had a vasectomy).

Torsion of the spermatic cord and torsion of a testicular appendage would be the main differential diagnosis considerations. Spermatic cord torsion is normally diagnosed using ultrasonography, which is very sensitive and specific, or with surgical exploration. The latter does not alter the outcome of epididymitis if the testicle is inadvertently explored to pursue torsion.

Of patients with orchitis resulting from tuberculosis, 70% have other genitourinary or pulmonary symptoms of this disease. Testing urine for acid-fast bacilli (AFB), testing using purified-protein derivative (PPD), and performing chest radiography are helpful.

Testicular cancer is the most common malignancy in males aged 15-35 years. Although it usually presents as a painless intraparenchymal mass, 10% of cases present after minor trauma. For this reason, any patient felt to have a lesion within the parenchyma of the testicle should be referred for immediate urologic evaluation.

Cystitis Workup

Microscopic hematuria is found in approximately 50% of cystitis cases; when microscopic hematuria is found without symptoms or pyuria, it should prompt a search for malignancy. Other conditions that should be considered include calculi, vasculitis, renal tuberculosis, and glomerulonephritis. In a developing country, hematuria is suggestive of schistosomiasis, which can be associated with salmonellosis and squamous cell malignancies of the bladder.

Urethritis Workup

In younger men, differentiation of UTI from urethritis may necessitate a urethral smear and culture or urinary antigen testing for chlamydia and N gonorrhoeae.

For urethritis, a urethral swab obtained 1 hour after the last micturition is 95% sensitive and 99% specific for gonorrhea. Inflammatory cells without intracellular gram-negative diplococci suggest nongonococcal urethritis (NGU).

A small swab should be carefully inserted approximately 1 inch into the male urethra and rotated about its axis 5 times. The swab then should be withdrawn and immediately streaked onto either chocolate agar or Thayer-Martin/New York City media. The same swab then should be rolled onto a slide, which should then be heat-fixed and stained (ie, Gram stain). Importantly, roll the specimen on only a very limited part of the slide; this will make the microscopic search easier. The same swab then may be sent for chlamydia testing, although many public health facilities do not have the funds to test males for this disease.

Chocolate agar is heated blood agar; the heating causes the red blood cells (RBCs) to lyse, releasing their intracellular contents, thereby enhancing the recovery of fastidious organisms such as N gonorrhea. This media is perfectly suited for culturing the male urethra, which is normally sterile. Thayer-Martin and New York City agars have antibiotics (including vancomycin) incorporated into them, thereby limiting the growth of competing bacteria that may overgrow the gonococcus.

These media are perfect for culturing the female cervix, the pharynx, or the anus. They also can be used for the male urethra, although the vancomycin may actually inhibit the growth of the gonococcus, creating a false-negative culture result. All neisserial growths must be confirmed as gonorrhea with a quadFERM test (a 2h carbohydrate degradation method for detecting Neisseria species); gonorrhea will only change the color in the glucose well.

Approach Considerations

As a general rule, all urinary tract infections (UTIs) in men are considered complicated. Therefore, the possibility that infection has ascended to the kidneys must be considered, and treatment regimens must assume that infection of the upper urinary tract has occurred. Urine culture results allow adjustment of the treatment plan if antibiotic sensitivity testing demonstrates a resistant organism.

In elderly patients, pyelonephritis carries a 3% mortality rate. Take a conservative management approach with these patients.

The decision to treat young men who are sexually active for UTI versus sexually transmitted disease (STD) – related urethritis rests primarily on epidemiologic grounds (eg, recent new sexual partner, multiple sexual partners).


Consultation with a urologist is essential for the treatment of UTIs in adult males with the following:

The following are suggested consultations:

Pain specialists may be needed to control discomfort in patients with nonbacterial prostatitis. Chronic abacterial prostatitis shares the following with other chronic pain syndromes: (1) pain as a primary complaint; (2) discord between symptoms and findings; and (3) history of multiple unsuccessful treatments. Providers of alternative healing (eg, hypnotherapists) and a psychiatrist or psychologist also may be needed.

Outpatient Versus Inpatient UTI Management

Patients who are well appearing, have stable vital signs, are able to maintain oral hydration and comply with oral therapy, and have no significant comorbid conditions can be treated as outpatients with adequate follow-up arranged in 48-72 hours.

If the patient appears toxic, has obstructive uropathy, has stones, is unable to tolerate fluids by mouth, has significant comorbid disease, or otherwise is unable to care for himself at home, inpatient admission is recommended. For example, consider admission for UTI for elderly patients and patients who have diabetes, who are immunocompromised, or who show signs of dehydration, hyperpyrexia, or rigors.

Initial inpatient treatment includes intravenous (IV) antimicrobial therapy with a third-generation cephalosporin, such as ceftriaxone; a fluoroquinolone, such as ciprofloxacin; or an aminoglycoside. Antipyretics, analgesics, and adequate IV fluids to restore appropriate circulatory volume and promote adequate urinary flow are also important.


Administer antimicrobial therapy, initially given intravenously, such as a third-generation cephalosporin, a fluoroquinolone, or an aminoglycoside. In patients with risk factors associated with an unfavorable prognosis, such as old age, debility, renal calculi, recent hospitalization or instrumentation, diabetes, sickle cell anemia, underlying carcinoma, or intercurrent cancer chemotherapy, the antimicrobial coverage should be broadened and an antipseudomonal agent should be added.

Adult males with UTI should receive a 10- to 14-day course of antibiotics. Outpatient regimens include a fluoroquinolone, trimethoprim-sulfamethoxazole (TMP-SMZ), minocycline, or nitrofurantoin (should not be given if glomerular filtration rate < 50). Treat the symptom of dysuria with phenazopyridine.[12, 13, 14, 15]

Unfortunately, the prevalence of uropathogens resistant to TMP-SMZ, nitrofurantoin, and first-generation cephalosporins has continued to rise. There are data that suggest overall resistance to TMP-SMZ is approximately 25% (range, 10-45%), based on the area of the country, and resistance to nitrofurantoin is slightly higher. Although studies have indicated that resistance to fluoroquinolones has been acceptably low, more recent microbiologic data suggest that fluoroquinolone resistance, particularly on the West Coast, may be an increasing problem. Despite these concerns, fluoroquinolones remain the preferred initial drug therapy.[16]

Aminoglycoside-related complications

As previously stated, prolonged use of aminoglycosides (>2wk) is a complication risk factor, including for cranial nerve (CN) VIII damage (hearing loss and vestibular dysfunction). Fortunately, most aminoglycoside use in treating serious UTIs is limited to less than 1 week.

Unfortunately, monitoring for CN VIII dysfunction is less than optimal; by the time it is detectable (even subclinically, by weekly audiograms and/or electronystagmograms), the damage has been done and is irreversible. This is because of differences in half-lives between sera and because of the endolymph and perilymph that bathe the inner ear. However, monitoring allows the damage to be minimized. Remember that the auditory and vestibular systems function independently; therefore, consideration should be given to monitoring each.

Animal models suggest that doses of aminoglycosides given at night or to a patient who has been fasting or is dehydrated may be more ototoxic. The possibly protective roles of calcium and calcium channel blockers await further study.

Dietary considerations

Keeping the patient well hydrated is important, especially if an obstruction was recently relieved.

Drinking cranberry juice offers little benefit. Although it appears to inhibit E coli from adhering to human uroepithelium, the amounts of bacteriostatic hippuric acid that are present are unlikely to be clinically effective.

For complicated UTIs associated with struvite calculi, foods and vitamin supplements rich in phosphorus and magnesium are advised. Remember that divalent cations (eg, magnesium) can chelate oral fluoroquinolones, preventing their absorption from the gut.

Activity considerations

Bedrest and avoiding certain activities (eg, bike riding) may be beneficial in patients with prostatitis. For patients with category IIIB (chronic, noninflammatory, abacterial) prostatitis, bedrest for 2 weeks has been advocated. Sitting on ring cushions can be a simple way to minimize symptoms.

In urethritis, sexual activity may be resumed when both partners have completed treatment; barrier methods are encouraged. No one knows for certain when sexual activity may be resumed for the other topics discussed in this article.

Overview of Prostatitis Treatment

To eradicate prostatitis, therapeutic drug levels must be achieved within the prostatic acini. Other challenges include prostatic calculi (a nidus for infection), inspissated secretions and microabscesses, and biofilms produced by offending organisms. Bladder outlet obstruction promotes stasis (and thus infection).

Antimicrobial agents

Nitrofurantoin, sulfonamides, vancomycin, penicillins, and cephalosporins do not penetrate well into the prostate.

Antibiotics that penetrate well into the acid milieu of the prostate are nonpolar and lipid-soluble and have a high measure of acid strength, a small molecular radius, and low serum protein binding. Drugs that best fit these criteria are the fluoroquinolones, doxycycline, minocycline (particularly effective against methicillin-resistant Staphylococcus aureus [MRSA]), trimethoprim (available in the United States only as trimethoprim-sulfamethoxazole [TMP-SMZ]), rifampin, and erythromycin. Of this group, the fluoroquinolones appear to achieve the best tissue levels.

Erythromycin is used as a second-line agent when culture results are available.

The combination antimicrobial TMP-SMZ should generally be avoided. Only the TMP penetrates the prostate, and its sulfa component may be nephrotoxic. Generally, if TMP is not available because of formulary reasons, resort to quinolone or tetracycline.

Rifampin should never be used alone. It needs to be given with at least one other antibiotic to which the pathogen is sensitive, since resistance to rifampin develops quite quickly. Basically, rifampin should be given only under special circumstances.


Quinolones can be divided into first, second, third, and fourth generations. First-generation drugs (nalidixic acid) are not effective for prostatic infections. Third- and fourth-generation fluoroquinolones provide increased streptococcal and anaerobic coverage, which is not needed to treat prostatic infections.

The second-generation quinolones widely used to treat prostatic infection include ciprofloxacin, ofloxacin, norfloxacin, and levofloxacin. These drugs all are bactericidal against gram-negative bacilli; however, because of increased resistance, they are no longer recommended by the US Centers for Disease Control and Prevention (CDC) for N gonorrhoeae infections.[17]

Levofloxacin is most effective against susceptible strains of Enterococcus faecalis and has the advantage of once-daily dosing. Although all of the second-generation drugs are used to treat prostatitis, only ofloxacin has been approved by the US Food and Drug Administration (FDA) for this indication.

Antibiotic concentrations

Regarding antibiotic concentrations in the prostate, interpreting the literature is difficult because many different terms are used (eg, "mean concentration in prostatic tissue," "mean concentration in prostatic fluid, prostatic tissue/serum ratio, prostatic fluid/serum ratio," and "stromal/epithelial ratio"). Furthermore, these specimens are often obtained in patients with benign prostatic hypertrophy or carcinoma (ie, not prostatitis).

One also must note the host being tested; TMP-SMZ penetrates the dog prostate far better than it does the human prostate, probably because of differences in semen pH. Although some antibiotics appear to be more suitable by certain criteria, clinical efficacy is probably the bottom line.

Nonantimicrobial agents

Many nonantimicrobial agents are available for prostatitis. Narcotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and tricyclic antidepressants (TCAs; eg, amitriptyline) may be needed for pain relief. Hormonal manipulation with a 5-alpha-reductase inhibitor (finasteride) may decrease glandular inflammation; lycopene, prominent in tomato sauces, may also diminish glandular swelling.

Diazepam and baclofen may decrease sphincter or perineal muscle spasm. Alpha blockers may minimize ductal reflux and dysfunctional voiding.

Because of tadalafil’s possible effect in BPH, it may be useful in preventing recurrent UTIs.[18]

Nonpharmaceutical therapy

Nonpharmaceutical approaches may also be used for prostatitis. An example of "what's old is new" is prostate massage. For decades prior to the antibiotic era, prostate massage was the primary therapy for prostatitis. In difficult cases, repetitive prostate massage may be of benefit because of its potential for improving antibiotic penetration and improving drainage of clogged ducts.

Acute and Chronic Prostatitis Therapy

The primary management of prostatitis is medical therapy. In certain circumstances, however, surgical intervention may be required.

Acute bacterial prostatitis

The intensely inflamed prostate allows antimicrobials to easily pass from the plasma. Hospitalized patients with acute bacterial prostatitis can receive various antimicrobials; parenteral ampicillin and gentamicin are often used. In most cases, the fever resolves in 2 days.

Once improved, appropriate oral agents include TMP-SMZ or a fluoroquinolone (preferred). Therapy should be continued for a minimum of 4 weeks to prevent chronic bacterial prostatitis from developing. Analgesics and stool softeners may be helpful.

If the patient with acute prostatitis has significant urinary obstruction, a Foley catheter can be gently inserted. If this is too uncomfortable, a suprapubic cystotomy may be required. The catheter can usually be removed 1-2 days later.

Chronic bacterial prostatitis

Although chronic bacterial prostatitis is very difficult to cure medically, an attempt should be made to cure this condition with antimicrobial therapy.[19, 20, 21, 22] Long-term results with TMP-SMZ (15-60% cure rate) probably reflect the inability of sulfa drugs to penetrate the noninflamed prostate; the usual regimen is 1 double-strength TMP-SMZ dose twice a day for 3 months.

The combination of TMP with rifampin may be useful but needs further study in chronic bacterial prostatitis. Some evidence suggests that 30 days of a fluoroquinolone may be superior to TMP-SMZ.

Coverage for Chlamydia and Ureaplasma should be considered for patients with category IIIA prostatitis (ie, leukocytosis without demonstrable bacteria).

If therapy fails, appropriate management of chronic bacterial prostatitis is to either treat acute exacerbations or to try chronic suppressive therapy (using half-normal doses).

Antimicrobials are not needed for asymptomatic patients who have evidence of inflammation on biopsy specimens or in secretions (category IV prostatitis); however, antimicrobials should be considered for men who are infertile who have bacteria or inflammation in their semen.


Surgery is indicated only for a few specific conditions, including bladder neck obstruction, prostatic calculi (seen in the image below), and recurrent infection with the same bacteria.[3]

View Image

Prostatic calcifications in a male with a urinary tract infection.

Transurethral incision of the bladder neck benefits some patients with bladder neck obstruction; however, transurethral balloon dilatation of the prostate is not helpful. A partial transurethral prostatectomy (TURP) removes only part of the infected gland and, therefore, benefits only one third of patients.

Radical or total prostatectomy is usually not required or beneficial; complications include incontinence and impotence. Patients for whom a radical TURP or total prostatectomy should be considered are those with either prostatic calculi or those in whom the same bacteria have been consistently isolated from prostatic specimens. A prostate biopsy may confirm that the bacteria are actually originating from the prostate. These are rarely cured by antimicrobials alone; drainage is best achieved by an ultrasonographically guided needle.

Other surgical interventions may be needed to remove or address other complications, such as bladder calculi (seen in the image below).

View Image

Bladder calculi in a male with a urinary tract infection.

Epididymitis Therapy

For epididymitis, antibiotic treatment for patients younger than 35 years should target Chlamydia and gonococci. Ceftriaxone (intramuscular [IM] 250mg) followed by doxycycline (oral [PO] 100mg twice daily [bid] for 7-10 days) is usually effective.

Epididymitis therapy for older men should address enteric gram-negative rods. TMP-SMZ (double-strength, 1 dose PO bid) or a fluoroquinolone can be used; a 30-day course covers concomitant prostatic infection.

When risk factors for urosepsis are present, such as fever or urinary retention, the patient should be hospitalized and IV antibiotics should be started.

Of cases of acute scrotum, 90% are caused by epididymitis, torsion of the spermatic chord, and torsion of a testicular appendage.

Torsion of the spermatic cord must be assumed until proven otherwise, because unresolved torsion of the cord is likely to result in irreversible necrosis in less than 12 hours. Consultation with a urologist is mandatory in all but the most clear-cut cases for operative salvage of the torsed testicle.

The surgical intervention is detorsion and orchidopexy, with orchidopexy of the contralateral side (because this side is predisposed to torsion at a later date).

Pyelonephritis Therapy

Most patients with pyelonephritis should undergo imaging studies to rule out other lesions, and IV antibiotic treatment should be initiated empirically with an aminoglycoside and ampicillin. Third- and fourth-generation cephalosporins, a carbapenem, or aztreonam also provides broad gram-negative rod coverage.

Fluid resuscitation is important if the blood pressure is unstable or if the patient is very old.

IV antibiotics are usually continued until the patient is afebrile for 24 hours, and then oral therapy is prescribed to complete at least 14 days of treatment; 30 days of treatment are typically necessary, because most cases are due to chronic prostatitis.

Urologic consultation should be considered for patients whose condition does not respond rapidly to antibiotics. In one study, fever persisted for 3 days in 13% of hospitalized patients with pyelonephritis, but none had complications; prolonged fever was associated with high baseline creatinine levels, younger age, and a high peripheral white blood cell (WBC) count.

Emphysematous pyelonephritis

Patients with diabetes are prone to develop emphysematous pyelonephritis, which is characterized by gas formation in the urinary tract. It often requires immediate nephrectomy for survival.

Orchitis, Cystitis, and Urethritis Therapy


For viral orchitis, supportive therapy with scrotal support, cold compresses, and bedrest is all that is needed. The use of estrogens, gammaglobulin, and steroids has been advocated by some, but these have not been shown to decrease the risk of sterility or shorten the duration of symptoms. Symptoms usually resolve spontaneously in 7-10 days.

In cases of mumps orchitis, the patient and his family should be advised that sterility develops in up to 10% of affected individuals. Because no treatment is available for this entity, it is important that the measles-mumps-rubella (MMR) vaccine be administered in childhood and repeated in late adolescence.


For the few men with uncomplicated cystitis, TMP-SMZ can be used in areas where resistant E coli number less than 20%; alternatively, a fluoroquinolone can be used. The length of treatment should be 7-10 days.


For urethritis, ceftriaxone (125mg IM as a single dose) treats penicillinase-producing N gonorrhoeae. Treatment for nongonococcal urethritis (NGU) should also be given (doxycycline 100mg PO bid for 7 days).

Sexual partners should also be treated, and patient counseling regarding safe sex is paramount; cases need to be reported to public health departments.

UTI Prevention

Preprocedure prophylaxis, condom use, and appropriate use of urinary catheters can reduce the risk of infections and complications.[23]

Unfortunately, instillation of antimicrobial agents into the bladder (unidirectional flow from the bladder to the bag is best), placing antimicrobials in the urine-drainage bag (which breaks the closed-drainage system), use of methenamine, and rigorous meatal cleansing are of little benefit. A guideline from the Infectious Diseases Society of America (IDSA) advises against the routine addition of antimicrobials or antiseptics to the drainage bag of patients who are catheterized in an effort to reduce the risk of catheter-associated bacteriuria or catheter-associated UTI (CAUTI).[24]

Preoperative prophylaxis

Preoperative antibiotics can reduce complications. Procedures of concern include open, transurethral, or laser prostatectomy; transrectal prostate biopsy; cystoscopy in patients with preoperative bacteruria or a preoperative indwelling catheter; and renal transplantation. Before antibiotic coverage, the rate of septicemia from a transrectal biopsy was 5-10%; currently, the rate is less than 0.1%. Fluoroquinolones are the prophylactic drugs of choice for urologic procedures.

Post-transurethral prostatectomy (TURP) bacteriuria rates are approximately 10% in patients who receive systemic antibiotics, compared with approximately 35% in those who do not. Single-dose therapy is as effective as longer treatment courses.

Unfortunately, neither cefuroxime nor ciprofloxacin has been shown to reduce the rate of bacteriuria (approximately 20%) after lithotripsy.

The American Heart Association recommends antimicrobial prophylaxis to prevent bacterial endocarditis in patients with moderate- to high-risk cardiac conditions. High-risk conditions include the presence of prosthetic valves, the previous occurrence of bacterial endocarditis, complex cyanotic congenital heart diseases, and the presence of surgically constructed systemic pulmonic shunts. Moderate-risk conditions include most other congenital heart diseases, hypertrophic cardiac myopathy, and mitral prolapse with regurgitation.

For patients with moderate- or high-risk cardiac conditions, urologic procedures that warrant prophylaxis include prostate surgery, cystoscopy, and urethral dilatation; prophylaxis is not recommended for inserting a Foley catheter in a patient with uninfected urine.

Antibiotic regimens

Regimens for high-risk patients include ampicillin (or vancomycin) plus gentamicin. Ampicillin is given as 2000mg IM or IV within 30 minutes of starting the procedure; 6 hours later, 1000mg of ampicillin (or amoxicillin PO) is given once. Gentamicin is dosed at 1.5 mg/kg IV or IM (not to exceed 120mg) and is given only once, with the first dose of ampicillin. For patients allergic to ampicillin, 1000mg of vancomycin is given IV over 1-2 hours only once; it should be completed within 30 minutes of starting the procedure.

For kidney transplant recipients, TMP/SMZ (1 dose PO daily) beginning 2-4 days after surgery and continuing for 4-8 months was found to reduce the incidence rate of UTIs from 38% to 8% (especially after the catheter was removed), cut febrile hospital days and bacterial infections (during and after hospitalization) in half, and reduce graft rejection.

Regimens for moderate-risk patients include amoxicillin or vancomycin. Amoxicillin is given only once, in a 2000mg dose administered orally 1 hour before the procedure. For patients allergic to amoxicillin, 1000mg of vancomycin is given intravenously over 1-2 hours only once; it should be completed within 30 minutes of starting the procedure.

Prevention of STD-related infections

Condoms are useful in preventing sexually transmitted diseases (STD) such as urethritis; latex condoms help to prevent the transmission of the human immunodeficiency virus (HIV). Remember that these patients are at risk for more than 1 infection (gonorrhea, chlamydia, syphilis, hepatitis B, herpes, Trichomonas, HIV). The risk of acquiring HIV from an infected sexual partner is approximately 0.3% on average; the risk is 30-50% for herpes and gonorrhea. If abstaining is not an option, condoms are the best protection.

Prevention of CAUTIs

According to the IDSA 2009 guideline for the diagnosis, prevention, and treatment of CAUTI in adults, if an indwelling catheter has been in place for more than 2 weeks at the onset of CAUTI and remains indicated, the catheter should be replaced to promote continued resolution of symptoms and to reduce the risk of subsequent catheter-associated infection.[24]

The guideline also states that an indwelling catheter may be considered at the patient’s request in exceptional cases and when other approaches to management of incontinence have proven ineffective.[24]

According to the IDSA guideline, strategies to reduce the use of catheterization have been proven effective and may have more impact on the incidence of CAUTI and asymptomatic bacteriuria than other approaches addressed in the guidelines.[24]

The CDC 2009 guideline for the prevention of CAUTI states that catheter use and duration should be minimized in all patients, especially those at higher risk for CAUTI (women, elderly persons, patients with impaired immunity).[25] The CDC guideline recommends the following preventive measures[25] :

Appropriate indications for indwelling urethral catheters include the relief of bladder outlet obstruction, treatment of urinary incontinence in a patient with an open sacral wound, and monitoring of urine output; they are also indicated for use during prolonged surgical procedures.

The CDC guideline recommends that clinicians avoid the routine use of systemic antimicrobials to prevent CAUTI in patients requiring either short- or long-term catheterization.[25]

Polymicrobial bladder infections are not uncommon in catheterized patients, and nonpathogenic organisms can be significant in catheterized patients. According to the CDC guideline, in acute care hospital settings, aseptic technique and sterile equipment for catheter insertion must be used to minimize the risk of CAUTI.[25]

At least 7 steps can be taken to prevent CAUTIs. However, although these steps can postpone a UTI for weeks, they will not be totally successful in patients with long-term catheterization.

Step 1

Catheterization should be avoided when not required (catheters have been found to be unnecessary in 41-58% of patient days) and should be terminated as soon as possible.

Step 2

Suprapubic catheters are associated with a lower risk of UTI. For men who require long-term catheterization, local genitourinary complications (meatal erosion, prostatitis, epididymitis) may be reduced and patients may be more satisfied, but mechanical complications are increased. Contraindications include bleeding disorders, previous lower abdominal surgery or irradiation, and morbid obesity.

Step 3

Condom catheters are also associated with a lower risk of bacteriuria than are indwelling catheters, as long as the catheter is not manipulated frequently. However, these are difficult to use in uncircumcised men.

Step 4

Most patients using intermittent catheterization become bacteriuric within a few weeks. The incidence rate is 1-3% per insertion.

Step 5

Aseptic indwelling catheter insertion, a properly maintained closed-drainage system (with ports in the distal catheter for needle aspiration of urine[24] ), and unobstructed urine flow are essential. Catheters with hydrophilic coatings reduce or delay the onset of bacteriuria and are more comfortable for the patient. Only properly trained individuals who are skilled in the correct technique of aseptic catheter insertion and maintenance should take on this task.[25]

Step 6

Urinary catheters coated with silver also reduce the risk of CAUTI. Silver alloy seems to be more effective than silver oxide, and using these more expensive catheters in patients who are at highest risk is reasonable.[26]

Step 7

Because many CAUTIs occur in clusters, good handwashing before and after catheter care is essential.

See Urinary Catheterization in Men and Urinary Catheterization in Women for procedural information on catheterization.

Long-Term Monitoring

If a patient fails to respond to antibiotics, an abscess should be considered. Upper- and lower-tract studies (eg, helical CT scanning, ultrasonography, cystoscopy) are important to consider in older patients at risk for anatomic abnormalities.

Follow-up urine cultures are warranted in males with UTIs; however, follow-up urethral cultures are not routinely warranted unless the man is symptomatic, in which case the symptoms are likely to be the result of exogenous reinfection.

Consider admission for UTI for elderly patients and patients who have diabetes, who are immunocompromised, or who show signs of toxicity such as dehydration, hyperpyrexia, rigors, or inability to tolerate oral fluids or medications. Also admit if the patient is unable to care for himself.

Medication Summary

The goals of pharmacotherapy are to eradicate the infection, to reduce morbidity, and to prevent complications.

Because of antimicrobial-resistant N gonorrhoeae, it is important to carefully review relevant clinical history of the patient and precisely determine the etiology of urinary symptoms in males. If gonorrhea is suspected, a fluoroquinolone antibiotic should not be prescribed because of widespread fluoroquinolone resistance to N gonorrhoeae. Dual therapy with ceftriaxone IM/IV plus azithromycin PO is recommended by the CDC sexually transmitted diseases treatment guidelines.[27]

There appears to be no advantage to treating UTI for more than 7 days in males without complications of urologic abnormalities, immunosuppression, clinical prostatitis, pyelonephritis nephrolithiasis, and/or BPH.[28]

Fifty-four percent of Enterobacteriaceae UTIs with resistance to extended-spectrum cephalosporin recurred within a median time of 69 days.[29]

Ciprofloxacin (Cipro)

Clinical Context:  Ciprofloxacin is a fluoroquinolone with activity against pseudomonads, streptococci, methicillin-resistant S aureus (MRSA), S epidermidis, and most gram-negative organisms, but it has no activity against anaerobes. This agent inhibits bacterial deoxyribonucleic acid (DNA) synthesis and growth. Ciprofloxacin is indicated for urinary tract infections (UTIs) and chronic bacterial prostatitis.

Levofloxacin (Levaquin)

Clinical Context:  Levofloxacin is a fluoroquinolone with better gram-positive activity but less activity against Pseudomonas aeruginosa than ciprofloxacin. This agent is an active L-isomer of ofloxacin. Ciprofloxacin is indicated for complicated and uncomplicated urinary tract infections. It is also used for the treatment of chronic bacterial prostatitis.

Ofloxacin (Floxin)

Clinical Context:  Ofloxacin is a pyridine carboxylic acid derivative with broad-spectrum bactericidal effect. In adults aged 18 years or older, the dosing regimen is by the oral or intravenous (PO/IV) route 200-400mg twice daily (bid). Ofloxacin is FDA approved for the treatment of prostatitis due to E coli.

Trimethoprim (Proloprim, Trimpex)

Clinical Context:  Trimethoprim is a dihydrofolate reductase inhibitor that prevents tetrahydrofolic acid production in bacteria. This agent is active in vitro against a broad range of gram-positive and gram-negative bacteria, including uropathogens such as Enterobacteriaceae and Staphylococcus saprophyticus. Resistance is usually mediated by decreased cell permeability or alterations in the amount or structure of dihydrofolate reductase.

Trimethoprim also demonstrates synergy with sulfonamides, potentiating the inhibition of bacterial tetrahydrofolate production.

Trimethoprim-sulfamethoxazole (Bactrim, Bactrim DS, Septra, Septra DS)

Clinical Context:  Trimethoprim-sulfamethoxazole (TMP-SMZ) is a combination antimicrobial agent designed to take advantage of synergy between TMP and sulfonamides. The antibacterial activity of TMP-SMZ includes common urinary tract pathogens, except Pseudomonas aeruginosa.

SMZ inhibits dihydropteroate synthetase, preventing incorporation of para-aminobenzoic acid (PABA) into dihydrofolate and subsequent synthesis of tetrahydrofolate. This agent has broad bacteriostatic activity against aerobic gram-positive and gram-negative organisms, with little activity against anaerobes; unfortunately, SMZ does not penetrate well into the kidney.

Ampicillin (Omnipen, Polycillin, Principen)

Clinical Context:  Ampicillin is an aminopenicillin beta lactam that impairs cell wall synthesis in actively dividing bacteria by binding to and inhibiting penicillin-binding proteins in the cell wall. This agent has enhanced activity against anaerobes and gram-negative aerobes and is generally used in combination with an aminoglycoside for empiric or directed activity against E faecalis urinary tract infections (UTIs).

Amoxicillin (Moxatag, Trimox)

Clinical Context:  Amoxicillin is a penicillin antibiotic that interferes with the synthesis of cell wall mucopeptides during active multiplication, resulting in bactericidal activity against susceptible bacteria.

Gentamicin (Garamycin, Gentacidin)

Clinical Context:  Gentamicin is a bactericidal aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the ribosome. This agent has activity against a variety of aerobic gram-negative bacteria, as well as E faecalis and staphylococcal species, and it is used with or without ampicillin to treat acute prostatitis in the hospitalized patient when Enterococcus is a concern. Gentamicin is the only aminoglycoside with appreciable activity against gram-positive organisms.

The dosing regimens for gentamicin are numerous. Adjust the dose based on creatinine clearance (CrCl) and changes in the volume of distribution. Ideal body weight (IBW) should be used for calculations (the drug is not fat soluble).

Trough serum levels should be monitored to ensure adequate clearance and reduce toxicity (< 2 mcg/mL). Peak levels should also be monitored after 4-5 half-lives when it is dosed more often than once daily (qd).

Once-daily dosing should only be used when treating gram-negative infections, as this takes advantage of its concentration-dependent killing and its postantibiotic effect. However, gentamicin exhibits neither of these properties against gram-positive infections. (For synergy against gram-positive organisms, use 1 mg/kg q8h).

Tobramycin (TOBI)

Clinical Context:  Tobramycin is an aminoglycoside used for gram-negative bacterial coverage, with better pseudomonal coverage than gentamicin. This agent is commonly used in combination with agents against gram-positive organisms and those that cover anaerobes.

Consider using tobramycin when penicillins or other less-toxic drugs are contraindicated, when bacterial susceptibility tests and clinical judgment indicate its use, and in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. Its dosing regimens are numerous and are adjusted based on the CrCl and changes in the volume of distribution.

Plazomicin (Zemdri)

Clinical Context:  Semisynthetic aminoglycoside antibacterial derived from sisomicin. Plazomicin has been engineered to overcome aminoglycoside-modifying enzymes (AMEs), the most common aminoglycoside-resistance mechanism in Enterobacteriaceae, and has in vitro activity against extended-spectrum beta-lactamase–producing, aminoglycoside-resistant, and carbapenem-resistant isolates. It is indicated for complicated urinary tract infections (cUTIs), including pyelonephritis caused by the following susceptible microorganism(s): E coli, K pneumoniae, P mirabilis, and E cloacae. Limited clinical safety and efficacy data are available; therefore, the prescribing information recommends to reserve treatment for use in patients with cUTI who have limited or no alternative treatment options.

Ceftriaxone (Rocephin)

Clinical Context:  Ceftriaxone is a third-generation cephalosporin that has a broad gram-negative spectrum, lower efficacy against gram-positive organisms, and higher efficacy against resistant organisms. By binding to 1 or more penicillin-binding proteins, this agent arrests bacterial cell wall synthesis and inhibits bacterial growth.

Ceftazidime (Fortaz, Tazicef)

Clinical Context:  Ceftazidime is a third generation cephalosporin and a bactericidal agent that exerts its effect by inhibiting the enzymes responsible for cell wall synthesis. Caution should be used with this agent, as nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.

In addition, chloramphenicol has been demonstrated to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli. Because of the possibility of antagonism in vivo, particularly when bactericidal activity is desired, avoid this drug combination.

Cefiderocol (Fetroja)

Clinical Context:  Cephalosporin antibiotic with a novel mechanism for penetrating the outer cell membrane of gram-negative pathogens by acting as a siderophore by binding to extracellular free ferric iron. Elicits bactericidal action by inhibiting cell wall biosynthesis through binding to penicillin-binding proteins. It is indicated for complicated UTIs, including pyelonephritis, caused by susceptible gram-negative microorganisms in adults who have limited or no alternative treatment options.

Erythromycin (Erythrocin, Ery-Tab)

Clinical Context:  Erythromycin is a macrolide antibiotic that inhibits bacterial growth, possibly by blocking dissociation of peptidyl transfer ribonucleic acid (tRNA) from ribosomes, causing RNA-dependent protein synthesis to arrest. It is used for the treatment of staphylococcal and streptococcal infections.

Vancomycin (Firvanq, Vancocin)

Clinical Context:  Vancomycin is a potent antibiotic directed against gram-positive organisms and active against Enterococcus species. It is indicated for patients who cannot receive or have failed to respond to penicillins and cephalosporins or who have infections with resistant staphylococci. It is used in conjunction with gentamicin for prophylaxis in penicillin-allergic patients undergoing gastrointestinal or genitourinary procedures.

Doxycycline (Vibramycin, Vibra-Tabs)

Clinical Context:  Doxycycline is a broad-spectrum, bacteriostatic antibiotic in the tetracycline class. It inhibits protein synthesis and, thus, bacterial growth by binding to the 30S and, possibly, the 50S ribosomal subunits of susceptible bacteria. It may block dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest.

Ertapenem (Invanz)

Clinical Context:  Ertapenem has bactericidal activity from inhibition of cell wall synthesis, which is mediated through ertapenem binding to penicillin-binding proteins. This agent is stable against hydrolysis by a variety of beta lactamases, including penicillinases, cephalosporinases, and extended-spectrum beta lactamases. Ertapenem is hydrolyzed by metallo–beta lactamases.

Aztreonam (Azactam, Cayston)

Clinical Context:  Aztreonam is a monobactam that inhibits cell wall synthesis during bacterial growth. It is active against gram-negative bacilli but has very limited gram-positive activity and is not useful against anaerobes. It lacks cross sensitivity with beta-lactam antibiotics, and it may be used in patients allergic to penicillins or cephalosporins.

Nitrofurantoin (Macrodantin, Furadantin)

Clinical Context:  Nitrofurantoin is a bactericidal antibiotic indicated for acute cystitis and UTIs caused by E coli, enterococci, S aureus, and strains of Klebsiella and Enterobacter species.

Rifampin (Rifadin)

Clinical Context:  Rifampin is an antituberculosis agent that inhibits RNA synthesis in bacteria by binding to the beta subunit of DNA-dependent RNA polymerase, which, in turn, blocks RNA transcription.

Imipenem/cilastatin/relebactam (Recarbrio)

Clinical Context:  Three-drug combination containing previously approved imipenem/cilastatin and relebactam, a beta-lactamase inhibitor. It is indicated for complicated urinary tract infections, including pyelonephritis, and complicated intra-abdominal infections in adults with limited or no other treatment options. Dosage modifications are necessary for patients who have renal impairment.

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.


Clinical Context:  Phenazopyridine is compatible with antibacterial therapy and can help to relieve pain and discomfort before antibacterial therapy controls infection. It is used for symptomatic relief of pain, burning, urgency, frequency, and other discomfort arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or passage of sounds or catheters. The analgesic action may reduce or eliminate the need for systemic analgesics or narcotics.

Class Summary

Urinary analgesics, such as phenazopyridine, can help to treat the symptoms of dysuria.

Why are urinary tract infections (UTIs) in males considered complicated?What are the signs and symptoms of urinary tract infection (UTI) in men?Which clinical findings indicate urinary tract infection (UTI) in males?What is the role of lab testing in the diagnosis of urinary tract infection (UTI) in males?When should imaging studies be used in the diagnosis of urinary tract infection (UTI) in men?When is inpatient management recommended for urinary tract infection (UTI) in males?How is urinary tract infection (UTI) in males treated?When is surgery indicated in the treatment of urinary tract infection (UTI) in males?What is the incidence of urinary tract infection (UTI) in men?What are possible complications of urinary tract infection (UTI) in males?What are the risk factors for developing complications in males with urinary tract infections (UTIs)?What do male patients with urinary tract infection (UTI) need to know?How does male anatomy protect against urinary tract infection (UTI)?What are the causes and complications of epididymitis?What is the pathophysiology of urinary tract infection (UTI) in males?How does the etiology of acute and chronic prostatitis differ?How does the NIH categorize chronic prostatitis?What causes relapsing urinary tract infection (UTI) in men?What is the pathophysiology of epididymitis?What is the etiology and pathophysiology of orchitis?What is the etiology and pathophysiology of pyelonephritis?Which clinical findings indicate bacterial cystitis?What is the pathophysiology of gonococcal urethritis?How does the presence of a urinary catheter affect the risk of urinary tract infection (UTI) in males?What are the risk factors for urinary tract infection (UTI) in males?Which pathogens cause prostatitis?Which are the most common pathogens associated with epididymitis?Which pathogens cause orchitis?Which pathogens cause pyelonephritis and cystitis in males?Which pathogens cause urethritis in men?What is the prevalence of catheter-associated urinary tract infection (UTI) in men and how does it develop?What is the prevalence of urinary tract infection (UTI) in males?What is the prevalence of prostatitis?How does the etiology of epididymitis differ by age groups?Among which demographic groups is gonococcal urethritis more common?What is the prevalence of mumps orchitis?What should be considered in the medical history of men with urinary tract infection (UTI)?Which physical exams should be performed in males who present with genitourinary complaints?Which physical findings are associated with urinary tract infection (UTI) in males?What are signs and symptoms of prostatitis syndromes?What is the typical presentation of acute prostatitis and which physical exams should be performed?How is chronic prostatitis differentiated from similar clinical entities such as prostatodynia or nonbacterial prostatitis?What are the symptoms and physical findings of epididymitis?What are the symptoms and physical findings of cystitis in males?What are the common presentations of orchitis?What are the symptoms and physical findings of pyelonephritis?What are the differential diagnoses of pyelonephritis in men?What is the incubation period and symptoms of gonococcal urethritis in men?How is urinary tract infection (UTI) in catheterized and/or hospitalized males diagnosed?How is urinary tract infection (UTI) differentiated from urethritis in males?What are the infectious and noninfectious causes of pyuria in males?Which possible comorbidities should be considered in the differential diagnoses of prostatitis?How are the diagnoses of epididymitis, torsion of the spermatic cord, and torsion of a testicular appendage differentiated?What factors should be considered in the differential diagnosis of cystitis in men?How are emphysematous and xanthogranulomatous pyelonephritis diagnosed in men?How is male genital tuberculosis diagnosed?What are the differential diagnoses for Urinary Tract Infection (UTI) in Males?What is the routine workup of suspected urinary tract infection (UTI) in males?What is the role of urinary studies in the diagnosis of urinary tract infection (UTI) in males?What is the role of imaging studies in the diagnosis of urinary tract infection (UTI) in males?Is plain film imaging useful for the diagnosis of urinary tract infection (UTI) in males?When is ultrasonography performed in males with urinary tract infection (UTI)?What is the role of CT scanning in the diagnosis of urinary tract infection (UTI) in males?Which histologic findings are associated with prostatitis?Which tests should be performed in the diagnosis of pyuria in men?Which tests should be performed in the diagnosis of prostatitis?Which tests are helpful in the diagnosis of epididymitis?Which tests are helpful in the diagnosis of orchitis?Which workup findings are associated with cystitis in males?Which tests should be performed in the diagnosis of urethritis in males?What should be considered prior to beginning treatment of urinary tract infection (UTI) in men?When should a urologist be consulted in the treatment of urinary tract infection (UTI) in men?In addition to a urologist, what other consultations are advisable in the treatment of urinary tract infection (UTI) in men?When is consultation with a pain specialist advisable for males with a urinary tract infection (UTI)?When is inpatient treatment of men with urinary tract infection (UTI) recommended?Which antimicrobials are used in the treatment of urinary tract infection (UTI) in males?What is the prevalence antibiotic resistance in the treatment of urinary tract infection (UTI) in men?What are the possible adverse effects of prolonged use of aminoglycoside in treatment of urinary tract infection (UTI) in males?Which dietary modifications are useful in the treatment of males with urinary tract infection (UTI)?Which activity restrictions are helpful in males with urinary tract infection (UTI)?What are the challenges during treatment of prostatitis?Which antibiotics are most effective in the treatment of prostatitis?Why is trimethoprim-sulfamethoxazole avoided in the treatment of prostatitis?Should rifampin be used to treat prostatitis?What is the role of quinolones in the treatment of prostatitis?Which antibiotic concentrations should be used in the treatment of prostatitis?What are the indications for nonantimicrobial agents in the treatment of prostatitis?What are the benefits of prostate massage in the treatment of prostatitis?How is acute bacterial prostatitis treated?How is chronic bacterial prostatitis treated?When is surgery indicated for prostatitis and which surgical interventions should be considered?Which antibiotics are used to treat epididymitis in young men?Which antibiotics are used to treat epididymitis in older men?When is inpatient treatment indicated for patients with epididymitis?How is acute scrotum treated?How is pyelonephritis treated in males?When is urologist consultation indicated for male patients with pyelonephritis?How can diabetes affect a male patient&#39;s risk of pyelonephritis?How is orchitis treated?What is the antimicrobial treatment for uncomplicated cystitis in men?What is the treatment for urethritis in men?How can urinary tract infection (UTI) in males be prevented?What is the efficacy of preoperative prophylaxis for male patients with urinary tract infection (UTI)?What are the AHA guidelines for antimicrobial prophylaxis to prevent bacterial endocarditis following urologic procedures?Which antibiotic regimens are indicated to prevent urinary tract infection (UTI) in males undergoing urologic procedures?Which prophylactic antibiotic regimen is used to reduce the risk of urinary tract infection (UTI) in male kidney transplant recipients?Which prophylactic antibiotic regimens are available for men who are at moderate risk of urinary tract infection (UTI)?How can STD-related infection be prevented in men?What are the IDSA guidelines for reduction in the use of catheterization in order to prevent catheter-associated urinary tract infections (CAUTIs) in men?What are the CDC guidelines for antimicrobial therapy to prevent catheter-associated urinary tract infection (CAUTI) in men?What are the CDC guidelines for acute care hospitals to reduce the risk of catheter-associated urinary tract infection (CAUTI) in men?What steps can be taken to reduce the risk of catheter-associated urinary tract infection (CAUTI) in men?What should be considered if antibiotic treatment fails in a male patient with urinary tract infection (UTI)?When are follow-up urine cultures necessary in male patients with urinary tract infection (UTI)?Which comorbidities may indicate the need for inpatient treatment for urinary tract infection (UTI) in men?What are the considerations for antibiotic therapy used to treat urinary tract infection (UTI) in males?Which medications in the drug class Antibiotics are used in the treatment of Urinary Tract Infection (UTI) in Males?Which medications in the drug class Analgesics, Urinary are used in the treatment of Urinary Tract Infection (UTI) in Males?


John L Brusch, MD, FACP, Assistant Professor of Medicine, Harvard Medical School; Consulting Staff, Department of Medicine and Infectious Disease Service, Cambridge Health Alliance

Disclosure: Nothing to disclose.


Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD, David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Disclosure: Nothing to disclose.


Bryan P Blair, MD Staff Physician, Department of Urology, Naval Medical Center at Portsmouth

Disclosure: Nothing to disclose.

David S Howes, MD Professor of Medicine and Pediatrics, Section Chief and Emergency Medicine Residency Program Director, University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine

David S Howes, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Physicians-American Society of Internal Medicine, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Klaus-Dieter Lessnau, MD, FCCP Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory; Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital

Klaus-Dieter Lessnau, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Thoracic Society, and Society of Critical Care Medicine

Disclosure: Sepracor None None

Mark Jeffrey Noble, MD Consulting Staff, Urologic Institute, Cleveland Clinic Foundation

Mark Jeffrey Noble, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, American Urological Association, Kansas Medical Society, Sigma Xi, Society of University Urologists, and Southwest Oncology Group

Disclosure: Nothing to disclose.

M Tyson Pillow, MD Assistant Director of Medical Education, Ben Taub General Hospital Emergency Center; Assistant Professor, Baylor College of Medicine

M Tyson Pillow, MD is a member of the following medical societies: Air Medical Physician Association, American College of Emergency Physicians, American Medical Association, American Medical Student Association/Foundation, Emergency Medicine Residents Association, Society for Academic Emergency Medicine, and Student National Medical Association

Disclosure: Nothing to disclose.

Joseph A Salomone III, MD Associate Professor and Attending Staff, Truman Medical Centers, University of Missouri-Kansas City School of Medicine; EMS Medical Director, Kansas City, Missouri

Joseph A Salomone III, MD is a member of the following medical societies: American Academy of Emergency Medicine, National Association of EMS Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Erik D Schraga, MD Staff Physician, Department of Emergency Medicine, Mills-Peninsula Emergency Medical Associates

Disclosure: Nothing to disclose.

Richard H Sinert, DO Associate Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, Research Director, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center

Richard H Sinert, DO is a member of the following medical societies: American College of Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Cindy L Tamminga, MD Consulting Staff, Division of Infectious Diseases, Naval Medical Center at Portsmouth

Disclosure: Nothing to disclose.


  1. Lafon T, Hernandez Padilla AC, Baisse A, Lavaud L, Goudelin M, Barraud O, et al. Community-acquired Staphylococcus aureus bacteriuria: a warning microbiological marker for infective endocarditis?. BMC Infect Dis. 2019 Jun 7. 19 (1):504. [View Abstract]
  2. Sante L, Aguirre-Jaime A, Miguel MA, Ramos MJ, Pedroso Y, Lecuona M. Epidemiological study of secondary bloodstream infections: The forgotten issue. J Infect Public Health. 2019 Jan - Feb. 12 (1):37-42. [View Abstract]
  3. Doluoglu OG, Gokkaya CS, Aktas BK, et al. Impact of asymptomatic prostatitis on re-operations due to urethral stricture or bladder neck contracture developed after TUR-P. Int Urol Nephrol. 2012 Jan 18. [View Abstract]
  4. van der Starre WE, van Nieuwkoop C, Paltansing S, et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother. 2011 Mar. 66(3):650-6. [View Abstract]
  5. Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol. 1968 Mar. 5(5):492-518. [View Abstract]
  6. Chung SD, Keller JJ, Lin HC. A case-control study of chronic prostatitis/chronic pelvic pain syndrome and colorectal cancer. BJU Int. 2012 Feb 7. [View Abstract]
  7. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002 Jul 8. 113 Suppl 1A:5S-13S. [View Abstract]
  8. Johnson JR. Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis. 2004 Sep 15. 39(6):873; author reply 873-4. [View Abstract]
  9. Chiang IN, Chang SJ, Pu YS, Huang KH, Yu HJ, Huang CY. Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: a retrospective study of 1875 cases in Taiwan. J Formos Med Assoc. 2007 Nov. 106(11):929-34. [View Abstract]
  10. Nickel JC. The Pre and Post Massage Test (PPMT): a simple screen for prostatitis. Tech Urol. 1997 Spring. 3(1):38-43. [View Abstract]
  11. Daunt SW. Accuracy of ultrasonography and plain-film abdominal radiography in the diagnosis of urologic abnormalities in men with urinary tract infection: critically appraised topic. Can Assoc Radiol J. 2004 Feb. 55(1):16-7. [View Abstract]
  12. Guay DR. Contemporary management of uncomplicated urinary tract infections. Drugs. 2008. 68(9):1169-205. [View Abstract]
  13. Howes DS, Bogner MP. Urinary tract infections. Tintinalli JE, Kelen GD, Stapczyski JS, eds. Emergency Medicine: A Comprehensive Study Guide. 7th ed. New York, NY: McGraw-Hill; 2008.
  14. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis. 2008 Nov 1. 47(9):1150-8. [View Abstract]
  15. Cunha BA. Antibiotic Essentials. 7th ed. Royal Oak, Mich: Physicians Press.; 2008.
  16. Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother. 2004 Jul-Aug. 38(7-8):1148-52. [View Abstract]
  17. [Guideline] Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006 Aug 4. 55:1-94. [View Abstract]
  18. Douglas D. Tadalafil confirmed as helpful in LUTS/BPH. Reuters Health Information. August 20, 2013. Available at http://www.medscape.com/viewarticle/809664. Accessed: August 29, 2013.
  19. Wagenlehner FM, Naber KG. Fluoroquinolone Antimicrobial Agents in the Treatment of Prostatitis and Recurrent Urinary Tract Infections in Men. Curr Infect Dis Rep. 2005 Jan. 7(1):9-16. [View Abstract]
  20. Wagenlehner FM, Naber KG. Current challenges in the treatment of complicated urinary tract infections and prostatitis. Clin Microbiol Infect. 2006 May. 12 Suppl 3:67-80. [View Abstract]
  21. Luzzi G. Chronic prostatitis. N Engl J Med. 2007 Jan 25. 356(4):423-4; author reply 424. [View Abstract]
  22. Wagenlehner FM, Weidner W, Naber KG. Therapy for prostatitis, with emphasis on bacterial prostatitis. Expert Opin Pharmacother. 2007 Aug. 8(11):1667-74. [View Abstract]
  23. Yoon BI, Kim S, Han DS, et al. Acute bacterial prostatitis: how to prevent and manage chronic infection?. J Infect Chemother. 2012 Jan 5. [View Abstract]
  24. [Guideline] Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010 Mar 1. 50(5):625-63. [View Abstract]
  25. [Guideline] Gould CV, Umscheid CA, Agarwal RK, Kuntz G, Pegues DA. Guideline for prevention of catheter-associated urinary tract infections 2009. Infect Control Hosp Epidemiol. 2010 Apr. 31(4):319-26. [View Abstract]
  26. Saint S, Elmore JG, Sullivan SD, Emerson SS, Koepsell TD. The efficacy of silver alloy-coated urinary catheters in preventing urinary tract infection: a meta-analysis. Am J Med. 1998 Sep. 105(3):236-41. [View Abstract]
  27. [Guideline] Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5. 64 (RR-03):1-137. [View Abstract]
  28. Germanos GJ, Trautner BW, Zoorob RJ, Salemi JL, Drekonja D, Gupta K, et al. No Clinical Benefit to Treating Male Urinary Tract Infection Longer Than Seven Days: An Outpatient Database Study. Open Forum Infect Dis. 2019 Jun. 6 (6):ofz216. [View Abstract]
  29. Anesi JA, Lautenbach E, Nachamkin I, Garrigan C, Bilker WB, Omorogbe J, et al. The role of extended-spectrum cephalosporin-resistance in recurrent community-onset Enterobacteriaceae urinary tract infections: a retrospective cohort study. BMC Infect Dis. 2019 Feb 14. 19 (1):163. [View Abstract]
  30. McNaughton Collins M, Fowler FJ Jr, Elliott DB, Albertsen PC, Barry MJ. Diagnosing and treating chronic prostatitis: do urologists use the four-glass test?. Urology. 2000 Mar. 55(3):403-7. [View Abstract]
  31. Porst H, Oelke M, Goldfischer ER, Cox D, Watts S, Dey D, et al. Efficacy and Safety of Tadalafil 5 mg Once Daily for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Subgroup Analyses of Pooled Data From 4 Multinational, Randomized, Placebo-controlled Clinical Studies. Urology. 2013 Jul 19. [View Abstract]
  32. Olson PD, Hruska KA, Hunstad DA. Androgens Enhance Male Urinary Tract Infection Severity in a New Model. J Am Soc Nephrol. 2015 Oct 8. [View Abstract]

Prostatic calcifications in a male with a urinary tract infection.

Prostatic calcifications in a male with a urinary tract infection.

Bladder calculi in a male with a urinary tract infection.

Prostatic calcifications in a male with a urinary tract infection.

Bladder calculi in a male with a urinary tract infection.